NASDAQ · IRD
Opus Genetics, Inc.
$3.43-$0.23 (-6.16%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.56% below the high.
Loading market information…
NASDAQ · LMNL · USD
Stock price, earnings
Quote as of Sep 25, 2023, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Liminal BioSciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Liminal BioSciences Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.43-$0.23 (-6.16%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.56% below the high.
$0.55$0.00 (0.0%)
Marinus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.76% below the high.
$1.00$0.00 (0.0%)
Angion Biomedica Corp.’s quoted price sits in the lower half of its reported 52-week range, 95.1% below the high.
$1.99+$0.10 (+5.29%)
Serina Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.2% below the high.
$0.33+$0.00 (+0.22%)
Allakos Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.9% below the high.
$6.49+$0.01 (+0.15%)
Freeline Therapeutics Holdings plc’s quoted price sits in the upper half of its reported 52-week range, 25.79% below the high.
$4.30-$0.14 (-3.15%)
AnPac Bio-Medical Science Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.14% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
